Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 10, 2006, Pages 4013-4021

  Mitsiades, Constantine S ^a,f   McMillin, Douglas ^a   Kotoula, Vassiliki ^b   Poulaki, Vassiliki ^a   McMullan, Ciaran ^a   Negri, Joseph ^a   Fanourakis, Galinos ^a,c   Tseleni Balafouta, Sophia ^c   Ain, Kenneth B ^d,e   Mitsiades, Nicholas ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d LEXINGTON VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN P21; PROTEIN P53;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MEDULLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID CARCINOMA;

EID: 33748744702     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2472     Document Type: Article

References (26)

1. Adams J 2004 The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349-360
2. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
3. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM 2004 Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22:115-119
4. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ 2004 Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121
5. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC 2002 Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086
6. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC 2003 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380
7. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC 2002 Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374-14379
8. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ 2005 Cancer statistics, 2005. CA Cancer J Clin 55:10-30
9. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S, Leonardi A 2004 Oncogenic and anti-apoptotic activity of NF-κB in human thyroid carcinomas. J Biol Chem 279:54610-54619
10. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, Bohm BO, Schmid RM 2001 Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 61:4526-4535
11. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
12. Gonsky R, Knauf JA, Elisei R, Wang JW, Su S, Fagin JA 1997 Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets. Nucleic Acids Res 25:3823-3831
13. Ain KB, Taylor KD, Tofiq S, Venkataraman G 1997 Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857-1862
14. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC 2001 TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795-804
15. Kaltschmidt C, Kaltschmidt B, Henkel T, Stockinger H, Baeuerle PA 1995 Selective recognition of the activated form of transcription factor NF-κB by a monoclonal antibody. Biol Chem Hoppe Seyler 376:9-16
16. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I 2000 Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60:4122-4129
17. Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S 2004 Inhibition of nuclear factor-κB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 89:410-418
18. Kubbutat MH, Jones SN, Vousden KH 1997 Regulation of p53 stability by Mdm2. Nature 387:299-303
19. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garcia-Echeverria C, Pearson MA, Hofmann F, Anderson KC, Kung AL 2004 Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230
20. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC 2002 Activation of NF-κB and up-regulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21:5673-5683
21. Landriscina M, Fabiano A, Altamura S, Bagala C, Piscazzi A, Cassano A, Spadafora C, Giorgino F, Barone C, Cignarelli M 2005 Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 90:5663-5671
22. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I 2002 p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1:493-503
23. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N 2000 Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053-1058
24. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari Jr AW, Lowe SW, Soengas MS 2005 Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65:6294-6304
25. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ 2005 Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65:6282-6293
26. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC 2005 Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058-3065